Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An emulation of a pragmatic trial in COHERE

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hepatic steatosis associated with exposure to elvitegravir and raltegravir

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of anal high-grade squamous intraepithelial lesions among renal transplant recipients compared with immunocompetent controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Response to Aviv et al

    Research output: Contribution to journalLetterResearchpeer-review

  2. Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A Atkinson
  • M Zwahlen
  • D Barger
  • A d'Arminio Monforte
  • S De Wit
  • J Ghosn
  • E Girardi
  • V Svedhem-Johansson
  • P Morlat
  • C Mussini
  • A Noguera-Julian
  • C Stephan
  • G Touloumi
  • O Kirk
  • A Mocroft
  • P Reiss
  • J M Miro
  • J R Carpenter
  • H Furrer
  • Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
View graph of relations

BACKGROUND: Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficiency virus (HIV) RNA (≤400 copies/mL), irrespective of CD4 count.

METHODS: We implemented an established causal inference approach whereby observational data are used to emulate a randomized trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their CD4 count was ≤200 cells/µL in line with existing recommendations. We compared the following 2 strategies for stopping prophylaxis: (1) when CD4 count was >200 cells/µL for >3 months or (2) when the patient was virologically suppressed (2 consecutive HIV RNA ≤400 copies/mL). Patients were artificially censored if they did not comply with these stopping rules. We estimated the risk of primary PcP in patients on ART, using the hazard ratio (HR) to compare the stopping strategies by fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias introduced by the artificial censoring.

RESULTS: A total of 4813 patients (10 324 person-years) complied with eligibility conditions for the emulated trial. With primary PcP diagnosis as an endpoint, the adjusted HR (aHR) indicated a slightly lower, but not statistically significant, different risk for the strategy based on viral suppression alone compared with the existing guidelines (aHR, .8; 95% confidence interval, .6-1.1; P = .2).

CONCLUSIONS: This study suggests that primary PcP prophylaxis might be safely withheld in confirmed virologically suppressed patients on ART, regardless of their CD4 count.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number2
Pages (from-to)195-202
Number of pages8
Publication statusPublished - 15 Jul 2021

    Research areas

  • HIV-RNA, human immunodeficiency virus, pneumocystis pneumonia, prophylaxis

ID: 60545895